<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00592111</url>
  </required_header>
  <id_info>
    <org_study_id>96-016</org_study_id>
    <secondary_id>CCG 5942</secondary_id>
    <secondary_id>CA42764</secondary_id>
    <nct_id>NCT00592111</nct_id>
  </id_info>
  <brief_title>A Comprehensive Study of Clinically Staged Pediatric Hodgkin's Disease: Chemotherapy for All Patients; Supplementary Low Dose Involved Field Irradiation for Selected Patients (CCG 5942)</brief_title>
  <official_title>A Comprehensive Study of Clinically Staged Pediatric Hodgkin's Disease: Chemotherapy for All Patients; Supplementary Low Dose Involved Field Irradiation for Selected Patients (CCG 5942)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Cancer Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      Study Hypothesis: Clinical staging without laparotomy/splenectomy is adequate for children
      and young adults with Hodgkin's disease who receive chemotherapy as a component of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 1996</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">February 1999</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the role of adjuvant low dose involved field radiotherapy in pediatric patients with Hodgkin's disease who attain a complete response following initial chemotherapy</measure>
    <time_frame>Conclusion of the study</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Pediatric</condition>
  <condition>Hodgkin's Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>COPP/ABV</intervention_name>
    <description>4 courses of COPP/ABV hybrid</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Cyclophosphamide</other_name>
    <other_name>Vincristine</other_name>
    <other_name>Procarbazine</other_name>
    <other_name>Prednisone</other_name>
    <other_name>Adriamycin</other_name>
    <other_name>Bleomycin</other_name>
    <other_name>Vinblastine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>COPP/ABV</intervention_name>
    <description>6 courses of COPP/ABV hybrid</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Cyclophosphamide</other_name>
    <other_name>Vincristine</other_name>
    <other_name>Procarbazine</other_name>
    <other_name>Prednisone</other_name>
    <other_name>Adriamycin</other_name>
    <other_name>Bleomycin</other_name>
    <other_name>Vinblastine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intensive chemo with concurrent growth factor</intervention_name>
    <description>6 cycles (2 courses) of intensive chemotherapy with concurrent growth factor</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Cyclophosphamide</other_name>
    <other_name>Vincristine</other_name>
    <other_name>Procarbazine</other_name>
    <other_name>Prednisone</other_name>
    <other_name>Adriamycin</other_name>
    <other_name>Bleomycin</other_name>
    <other_name>Vinblastine</other_name>
    <other_name>Cytosine Arabinoside</other_name>
    <other_name>Etoposide</other_name>
    <other_name>G-CSF (Filgrastim)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Age less than 21 years at diagnosis

          -  Previously untreated, pathologically confirmed diagnosis of Hodgkin's disease.

          -  Informed patient/parental consent as required by individual institution and in
             accordance with the Dept of Health and Human Services

          -  Approval of this protocol by the individual institutional Human Subjects Review
             Committee.

          -  Indicate Hodgkin's disease clinical stage.

          -  Indicate presence or absence of &quot;B&quot; symptoms.

          -  For Stage I and II disease indicate the following:

          -  presence or absence of bulk disease

          -  number of involved nodal regions

          -  presence or absence of hilar adenopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tanya Trippett, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
  </link>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2007</study_first_submitted>
  <study_first_submitted_qc>December 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2008</study_first_posted>
  <last_update_submitted>December 21, 2015</last_update_submitted>
  <last_update_submitted_qc>December 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediatric</keyword>
  <keyword>Hodgkin's Disease</keyword>
  <keyword>96-016</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Bleomycin</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Procarbazine</mesh_term>
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

